National Institutes of Health: Lymphoma trials

The registry lists 362 Lymphoma studies with National Institutes of Health as lead sponsor. 15 are open to participants now and 130 have results posted.

Early Phase 1 2Phase 1 181Phase 2 171Phase 3 7Phase 4 1No phase 38(a study in two phases counts in both)

Studies

Page 2 of 4. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell LymphomaCompletedNCT00703664Phase 2Results posted
• Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaCompletedNCT00553644Phase 2Results posted
• Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune SystemCompletedNCT00520130Phase 1/2Results posted
• Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell LymphomaCompletedNCT00445341Phase 1/2Results posted
• Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell LymphomaCompletedNCT00433537Phase 2Results posted
• Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00398112Phase 2Results posted
• Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell LymphomaCompletedNCT00392496Phase 2Results posted
• FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaTerminatedNCT00383565Phase 2Results posted
• Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous TherapyCompletedNCT00381940Phase 2Results posted
• SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell LymphomaTerminatedNCT00365274Phase 2Results posted
• Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell LymphomaTerminatedNCT00354107Phase 1/2Results posted
• SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT00337194Phase 2Results posted
• Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401)CompletedNCT00329030Phase 3Results posted
• PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's LymphomaCompletedNCT00303953Phase 2Results posted
• CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00290472Phase 2Results posted
• Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin LymphomaTerminatedNCT00288067Phase 1/2Results posted
• Chemotherapy and HAART to Treat AIDS-related Primary Brain LymphomaCompletedNCT00267865Phase 2Results posted
• Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's LymphomaCompletedNCT00253630Phase 2Results posted
• Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's LymphomaCompletedNCT00132028Phase 2Results posted
• Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's LymphomaCompletedNCT00131937Phase 2Results posted
• Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell LymphomaCompletedNCT00121199Phase 2Results posted
• 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's LymphomaCompletedNCT00117988Phase 2Results posted
• EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell LymphomaCompletedNCT00114738Phase 2Results posted
• Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaTerminatedNCT00112723Phase 1/2Results posted
• CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00109967Phase 2Results posted
• MDX-010 in Treating Patients With Recurrent or Refractory LymphomaTerminatedNCT00089076Phase 1/2Results posted
• Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's LymphomaTerminatedNCT00088881Phase 2Results posted
• Tipifarnib in Treating Patients With Relapsed or Refractory LymphomaCompletedNCT00082888Phase 2Results posted
• UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell LymphomasTerminatedNCT00082017Phase 2Results posted
• Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell LymphomasCompletedNCT00080535Phase 2Results posted
• Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph CancersTerminatedNCT00074490Phase 2Results posted
• Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell LymphomasCompletedNCT00069238Phase 2Results posted
• Campath-1H for Treating Adult T-Cell Leukemia/LymphomaCompletedNCT00061048Phase 2Results posted
• Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic LymphomaCompletedNCT00058240Phase 1/2Results posted
• Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaCompletedNCT00058019Phase 2Results posted
• PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's LymphomaCompletedNCT00054665Phase 2Results posted
• Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin LymphomaCompletedNCT00054639Phase 2Results posted
• Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's LymphomaCompletedNCT00049036Phase 2Results posted
• Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDSCompletedNCT00025662Phase 2Results posted
• Bortezomib in Treating Patients With Lymphoproliferative DisordersCompletedNCT00023764Phase 2Results posted
• Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaTerminatedNCT00012298Phase 1/2Results posted
• Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell LymphomaCompletedNCT00007345Phase 2Results posted
• Chemotherapy Plus Vaccination to Treat Mantle Cell LymphomaCompletedNCT00005780Phase 2Results posted
• Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid LeukemiaCompletedNCT00001575Phase 1/2Results posted
• Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's LymphomaCompletedNCT00001337Phase 2Results posted
• Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)WithdrawnNCT06400264Phase 2
• Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)Active, not recruitingNCT06400225Phase 2
• Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)Active, not recruitingNCT06390865Phase 2
• Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)Active, not recruitingNCT06385496Phase 2
• Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)WithdrawnNCT06210750Phase 2
• A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin LymphomaWithdrawnNCT05711628Phase 3
• Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell LymphomaActive, not recruitingNCT04739813Phase 1
• Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI StudyWithdrawnNCT04500548Phase 1
• Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)WithdrawnNCT04439305Phase 2
• Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and LymphomasWithdrawnNCT03925428Phase 1
• Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and LymphomaActive, not recruitingNCT03502733Phase 1
• Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver DysfunctionWithdrawnNCT03217253Phase 1
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
• Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell MalignanciesCompletedNCT02315612Phase 1
• Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated LymphomasWithdrawnNCT02228512Phase 1/2
• Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell LymphomaCompletedNCT02219737Phase 1
• Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid TumorsCompletedNCT02211755Phase 1
• Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV InfectionTerminatedNCT02109224Phase 1
• Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT01902160Phase 1
• Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell LymphomasCompletedNCT01897012Phase 1
• Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01886859Phase 1
• Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell TransplantCompletedNCT01822509Phase 1
• Indenoisoquinoline LMP400 for Advanced Solid Tumors and LymphomasCompletedNCT01794104Phase 1
• Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell LymphomaCompletedNCT01729806Phase 1
• Fluorodeoxyglucose Imaging Studies to Detect LymphomaWithdrawnNCT01672918
• Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver DysfunctionCompletedNCT01638533Phase 1
• Study of Lymphoma in AsiaCompletedNCT01584141
• Imetelstat for Children With Refractory or Recurrent Solid Tumors and LymphomaWithdrawnNCT01568632Phase 1
• Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell LymphomaCompletedNCT01567709Phase 1
• Proteomic-Based Profiling of Lymphomas: Chromatin Proteomics; Composition and Modification of Histone and Non-Histone Chromosomal ProteinsCompletedNCT01563874
• ABT-888 Plus Metronomic Cyclophosphamide to Treat CancerCompletedNCT01445522Phase 1
• Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell LymphomaTerminatedNCT01445340Phase 1
• MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell LymphomaWithdrawnNCT01415765Phase 1/2
• Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin LymphomaCompletedNCT01403415Phase 1
• Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancersCompletedNCT01254578Phase 1
• An Early Phase I Study of IPdR Absorption, Metabolism, and Safety in Patients With Advanced Solid Tumors and LymphomasCompletedNCT01240577Phase 1
• Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaWithdrawnNCT01238146Phase 1/2
• RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell LeukemiaWithdrawnNCT01236586Phase 1
• MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaCompletedNCT01231919Phase 1
• Epidemiology of Burkitt Lymphoma in East Africa Children or Minors (EMBLEM)CompletedNCT01196520
• RO4929097 and Capecitabine in Treating Patients With Refractory Solid TumorsCompletedNCT01158274Phase 1
• A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and LymphomasCompletedNCT01132911Phase 1
• Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic LeukemiaTerminatedNCT01126502Phase 1
• A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy VolunteersCompletedNCT01117142
• Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell LeukemiaTerminatedNCT01088763Phase 1
• Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT01076556Phase 1
• A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and LymphomasCompletedNCT01051635Phase 1
• Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and LymphomaCompletedNCT00994500Phase 1
• Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood DisordersTerminatedNCT00973804Phase 1
• Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or LeukemiaTerminatedNCT00933985Phase 1
• A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced MalignanciesCompletedNCT00923520Phase 1
• Assessing Arsenic Trioxide in Young Patients With Leukemia or Lymphoma Who Were Treated on Clinical Trial NCI-00-C-0070JCompletedNCT00899015
• Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT00891072Phase 1
• Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
• A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid MalignanciesCompletedNCT00861510Phase 1